Encompass Health (EHC) 10-Q 4 May 21 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2021	Apr. 22, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-10315
Entity Registrant Name	Encompass Health Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	63-0860407
Entity Address, Address Line One	9001 Liberty Parkway
Entity Address, City or Town	Birmingham
Entity Address, State or Province	AL
Entity Address, Postal Zip Code	35242
City Area Code	205
Local Phone Number	967-7116
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	EHC
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		99,542,410
Entity Central Index Key	0000785161
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement Of Comprehensive Income And Income Statement [Abstract]
Net operating revenues	$ 1,230.4	$ 1,182
Operating expenses:
Salaries and benefits	687.2	679.1
Other operating expenses	162.3	159.6
Occupancy costs	20.2	20.2
Supplies	51.9	45.7
General and administrative expenses	38.6	35.6
Depreciation and amortization	62.5	58.8
Government, class action, and related settlements	0	2.8
Total operating expenses	1,022.7	1,001.8
Interest expense and amortization of debt discounts and fees	42.8	43.2
Other (income) expense	(1.4)	1.9
Equity in net income of nonconsolidated affiliates	(1)	(0.8)
Income from continuing operations before income tax expense	167.3	135.9
Provision for income tax expense	34.5	27.1
Income from continuing operations	132.8	108.8
Loss from discontinued operations, net of tax	0	(0.1)
Net income	132.8	108.7
Comprehensive income	132.8	108.7
Less: Net income attributable to noncontrolling interests	(25.5)	(21.7)
Less: Comprehensive income attributable to noncontrolling interests	(25.5)	(21.7)
Net income attributable to Encompass Health	107.3	87
Comprehensive income attributable to Encompass Health	$ 107.3	$ 87
Weighted average common shares outstanding:
Basic (in shares)	99	98.2
Diluted (in shares)	100.2	99.6
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations (in dollars per share)	$ 1.08	$ 0.88
Discontinued operations (in dollars per share)	0	0
Net income (in dollars per share)	1.08	0.88
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations (in dollars per share)	1.07	0.87
Discontinued operations (in dollars per share)	0	0
Net income (in dollars per share)	$ 1.07	$ 0.87
Amounts attributable to Encompass Health common shareholders:
Income from continuing operations	$ 107.3	$ 87.1
Loss from discontinued operations, net of tax	0	(0.1)
Net income attributable to Encompass Health	$ 107.3	$ 87

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions		Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents		$ 223.9	$ 224
Restricted cash		62.2	65.4
Accounts receivable		633.6	572.8
Other current assets		81.4	86.4
Total current assets		1,001.1	948.6
Property and equipment, net		2,280.5	2,206.6
Operating lease right-of-use assets		248.3	245.7
Goodwill		2,318.7	2,318.7
Intangible assets, net		419.2	431.3
Other long-term assets		274.4	295
Total assets	[1]	6,542.2	6,445.9
Current liabilities:
Current portion of long-term debt		137.2	38.3
Current operating lease liabilities		44.2	44.8
Accounts payable		122.8	115
Accrued expenses and other current liabilities		508	519.2
Total current liabilities		812.2	717.3
Long-term debt, net of current portion		3,160	3,250.6
Long-term operating lease liabilities		214.2	209.6
Deferred income tax liabilities		60.6	51.8
Other long-term liabilities		220.5	215
Total liabilities		4,467.5	4,444.3
Commitments and contingencies
Redeemable noncontrolling interests		31.7	31.6
Shareholders’ equity:
Encompass Health shareholders’ equity		1,655.1	1,588
Noncontrolling interests		387.9	382
Total shareholders’ equity		2,043	1,970
Total liabilities and shareholders' equity	[1]	$ 6,542.2	$ 6,445.9
[1]	Our consolidated assets as of March 31, 2021 and December 31, 2020 include total assets of variable interest entities of $219.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2021 and December 31, 2020 include total liabilities of the variable interest entities of $44.6 million and $46.8 million, respectively. See Note 3, Variable Interest Entities.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions		Mar. 31, 2021	Dec. 31, 2020
Assets	[1]	$ 6,542.2	$ 6,445.9
Liabilities		4,467.5	4,444.3
VIE
Assets		219.2	221.2
Liabilities		$ 44.6	$ 46.8
[1]	Our consolidated assets as of March 31, 2021 and December 31, 2020 include total assets of variable interest entities of $219.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2021 and December 31, 2020 include total liabilities of the variable interest entities of $44.6 million and $46.8 million, respectively. See Note 3, Variable Interest Entities.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Capital in Excess of Par Value	Accumulated Deficit	Treasury Stock	Noncontrolling Interests
Balance at beginning of period (shares) at Dec. 31, 2019		98.6
Balance at beginning of period at Dec. 31, 2019	$ 1,693.1	$ 1.1	$ 2,369.9	$ (526.5)	$ (492.3)	$ 340.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	106.7			87		19.7
Receipt of treasury stock (shares)		(0.2)
Receipt of treasury stock	(15.6)				(15.6)
Dividends declared	(27.9)		(27.9)
Exchange of Holdings shares (shares)		0.6
Exchange of Holdings shares	46.3		27.1		19.2
Stock-based compensation	7.1		7.1
Distributions declared	(15.5)					(15.5)
Capital contributions from consolidated affiliates	5.8					5.8
Repurchases of common stock in open market (shares)		(0.1)
Repurchases of common stock in open market	(4.9)				(4.9)
Other (shares)		0.5
Other	2.1		0		(0.3)	2.4
Balance at end of period (shares) at Mar. 31, 2020		99.4
Balance at end of period at Mar. 31, 2020	1,797.2	$ 1.1	2,376.2	(439.5)	(493.9)	353.3
Balance at beginning of period (shares) at Dec. 31, 2020		99.4
Balance at beginning of period at Dec. 31, 2020	1,970	$ 1.1	2,326.6	(242.3)	(497.4)	382
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	130.4			107.3		23.1
Receipt of treasury stock (shares)		(0.2)
Receipt of treasury stock	(15.6)				(15.6)
Dividends declared	(27.8)		(27.8)
Stock-based compensation	2.8		2.8
Distributions declared	(22.4)					(22.4)
Capital contributions from consolidated affiliates	5.8					5.8
Other (shares)		0.4
Other	(0.2)		1.1		(0.7)	(0.6)
Balance at end of period (shares) at Mar. 31, 2021		99.6
Balance at end of period at Mar. 31, 2021	$ 2,043	$ 1.1	$ 2,302.7	$ (135)	$ (513.7)	$ 387.9

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]
Dividends declared on common stock (in dollars per share)	$ 0.28	$ 0.28

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net income	$ 132.8	$ 108.7
Loss from discontinued operations, net of tax	0	0.1
Adjustments to reconcile net income to net cash provided by operating activities—
Depreciation and amortization	62.5	58.8
Stock-based compensation	2.8	7.1
Deferred tax expense	8.7	1.4
Other, net	2	7.7
Change in assets and liabilities, net of acquisitions—
Accounts receivable	(55.1)	(36.6)
Other assets	1.3	15.8
Accrued payroll	5.7	(24)
Other liabilities	(2.2)	(109.6)
Net cash used in operating activities of discontinued operations	0	(0.1)
Total adjustments	25.7	(79.5)
Net cash provided by operating activities	158.5	29.3
Cash flows from investing activities:
Acquisitions of businesses, net of cash acquired	0	(1.1)
Purchases of property and equipment	(98.8)	(83.5)
Other, net	3.2	1.6
Net cash used in investing activities	(95.6)	(83)
Cash flows from financing activities:
Borrowings on revolving credit facility	0	330
Payments on revolving credit facility	0	(25)
Taxes paid on behalf of employees for shares withheld	(15.6)	(15.6)
Dividends paid on common stock	(29.1)	(29)
Distributions paid to noncontrolling interests of consolidated affiliates	(27.8)	(19.1)
Purchase of equity interests in consolidated affiliates	0	(162.3)
Other, net	(5)	(7.9)
Net cash (used in) provided by financing activities	(77.5)	71.1
(Decrease) increase in cash, cash equivalents, and restricted cash	(14.6)	17.4
Cash, cash equivalents, and restricted cash at beginning of period	310.9	159.6
Cash, cash equivalents, and restricted cash at end of period	296.3	177
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period	224	94.8
Restricted cash at beginning of period	65.4	57.4
Restricted cash included in other long-term assets at beginning of period	21.5	7.4
Cash, cash equivalents, and restricted cash at beginning of period	310.9	159.6
Cash and cash equivalents at end of period	223.9	104.9
Restricted cash at end of period	62.2	56.7
Restricted cash included in other long-term assets at end of period	10.2	15.4
Cash, cash equivalents, and restricted cash at end of period	$ 296.3	$ 177

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a leading provider of post-acute healthcare services, offering both facility-based and home-based patient services in 39 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See also Note 11, Segment Reporting . The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission on February 26, 2021 (the “2020 Form 10‑K”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December 31, 2020 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading. The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented. Net Operating Revenues — Our Net operating revenues disaggregated by payor source and segment are as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Consolidated Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, 2021 2020 2021 2020 2021 2020 Medicare $ 614.5 $ 641.9 $ 223.9 $ 226.2 $ 838.4 $ 868.1 Medicare Advantage 158.4 111.5 28.0 29.4 186.4 140.9 Managed care 112.2 90.2 14.3 12.1 126.5 102.3 Medicaid 39.0 30.7 3.8 4.2 42.8 34.9 Other third-party payors 12.1 11.0 — — 12.1 11.0 Workers’ compensation 5.7 6.9 0.1 0.3 5.8 7.2 Patients 4.9 5.5 0.2 0.4 5.1 5.9 Other income 13.1 11.5 0.2 0.2 13.3 11.7 Total $ 959.9 $ 909.2 $ 270.5 $ 272.8 $ 1,230.4 $ 1,182.0 See Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2020 Form 10-K for our policy related to Net operating revenues . Recently Adopted Accounting Pronouncements — In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. Either prospective or retrospective transition of this standard is dependent upon the specific amendments. The new guidance was effective for us beginning January 1, 2021. The adoption of this guidance did not have a material impact to our condensed consolidated financial statements. We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Business Combinations	Business Combinations Home Health and Hospice In April 2021, we announced we entered into a definitive agreement to purchase the home health and hospice assets of Frontier Home Health and Hospice in Alaska, Colorado, Montana, Washington, and Wyoming for a cash purchase price of $95 million. At closing, 9 home health and 11 hospice locations will become part of our national network of home health and hospice locations. This transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the second quarter of 2021. We expect to fund this transaction with cash on hand and borrowings under our revolving credit facility.

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities As of March 31, 2021 and December 31, 2020, we consolidated nine limited partnership-like entities that are variable interest entities (“VIEs”) and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 75.0% as of March 31, 2021. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities. The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our condensed consolidated balance sheet, are as follows (in millions): March 31, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 0.5 $ 0.1 Accounts receivable 33.7 33.1 Other current assets 8.5 8.6 Total current assets 42.7 41.8 Property and equipment, net 118.7 121.1 Operating lease right-of-use assets 4.4 4.7 Goodwill 19.2 19.2 Intangible assets, net 3.1 3.3 Other long-term assets 31.1 31.1 Total assets $ 219.2 $ 221.2 Liabilities Current liabilities: Current portion of long-term debt $ 0.9 $ 0.9 Current operating lease liabilities 1.5 1.5 Accounts payable 5.9 6.1 Accrued expenses and other current liabilities 21.7 23.0 Total current liabilities 30.0 31.5 Long-term debt, net of current portion 9.4 9.6 Long-term operating lease liabilities 2.9 3.3 Other long-term liabilities 2.3 2.4 Total liabilities $ 44.6 $ 46.8

Long-term Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt Our long-term debt outstanding consists of the following (in millions): March 31, 2021 December 31, 2020 Credit Agreement— Term loan facilities $ 248.3 $ 251.6 Bonds payable— 5.125% Senior Notes due 2023 298.3 298.1 5.75% Senior Notes due 2025 346.5 346.3 4.50% Senior Notes due 2028 785.5 785.0 4.75% Senior Notes due 2030 783.5 783.2 4.625% Senior Notes due 2031 393.3 393.2 Other notes payable 39.7 39.8 Finance lease obligations 402.1 391.7 3,297.2 3,288.9 Less: Current portion (137.2) (38.3) Long-term debt, net of current portion $ 3,160.0 $ 3,250.6 In March 2021, we issued notice for redemption of $100 million in outstanding principal amount of the 5.125% Senior Notes due 2023 (the “2023 Notes”). We completed this redemption on April 5, 2021 using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. As a result of this redemption, we have classified approximately $100 million of the 2023 Notes as current in our accompanying March 31, 2021 condensed consolidated balance sheet, and we expect to record an approximate $0.6 million loss on early extinguishment of debt in the second quarter of 2021.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	3 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interests	Redeemable Noncontrolling Interests The following is a summary of the activity related to our Redeemable noncontrolling interests (in millions): Three Months Ended March 31, 2021 2020 Balance at beginning of period $ 31.6 $ 239.6 Net income attributable to noncontrolling interests 2.4 2.0 Distributions declared (2.3) (2.1) Contribution to joint venture — 3.1 Purchase of redeemable noncontrolling interests — (162.3) Exchange transaction — (46.3) Balance at end of period $ 31.7 $ 34.0 The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net and comprehensive income attributable to noncontrolling interests presented in the condensed consolidated statements of comprehensive income (in millions): Three Months Ended March 31, 2021 2020 Net income attributable to nonredeemable noncontrolling interests $ 23.1 $ 19.7 Net income attributable to redeemable noncontrolling interests 2.4 2.0 Net income attributable to noncontrolling interests $ 25.5 $ 21.7 On December 31, 2014, we acquired 83.3% of our home health and hospice business when we purchased EHHI Holdings, Inc. (“EHHI”). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (“Holdings”), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. In January 2020, we received exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. On February 20, 2020, Encompass Health entered into exchange agreements (each, an “Exchange Agreement”) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the “EHC Shares”). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an “Exchange Notice”) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health’s common stock on the New York Stock Exchange (the “NYSE”) on the date of delivery of the Exchange Notice. On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors. Based on the last sales price of Encompass Health’s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns 100% of Holdings and EHHI. See also Note 6, Fair Value Measurements .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of March 31, 2021 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Valuation Technique (1) Other long-term assets: Equity securities $ 73.1 $ — $ 73.1 $ — M Redeemable noncontrolling interests 31.7 — — 31.7 I As of December 31, 2020 Other long-term assets: Equity securities $ 72.6 $ — $ 72.6 $ — M Redeemable noncontrolling interests 31.6 — — 31.6 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I). There are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the three months ended March 31, 2021 and March 31, 2020, we did not record any material gains or losses related to these assets. As discussed in Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” to the consolidated financial statements accompanying the 2020 Form 10‑K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions): As of March 31, 2021 As of December 31, 2020 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Term loan facilities $ 248.3 $ 249.8 $ 251.6 $ 253.1 5.125% Senior Notes due 2023 298.3 300.8 298.1 302.6 5.75% Senior Notes due 2025 346.5 361.6 346.3 361.4 4.50% Senior Notes due 2028 785.5 820.2 785.0 840.0 4.75% Senior Notes due 2030 783.5 824.0 783.2 856.0 4.625% Senior Notes due 2031 393.3 415.0 393.2 424.9 Other notes payable 39.7 39.7 39.8 39.8 Financial commitments: Letters of credit — 37.7 — 36.7 Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” to the consolidated financial statements accompanying the 2020 Form 10‑K.

Share-Based Payments

Share-Based Payments	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Payments	Share-Based Payments During the three months ended March 31, 2021, we issued a total of 0.5 million restricted stock awards to members of our management team and our board of directors. Approximately 0.2 million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company’s performance during the applicable two year performance measurement period. Additionally, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note 1, Summary of Significant Accounting Policies , and Note 14, Share-Based Payments , to the consolidated financial statements accompanying the 2020 Form 10‑K. In conjunction with the EHHI acquisition discussed in Note 5, Redeemable Noncontrolling Interests , we granted stock appreciation rights (“SARs”) based on Holdings common stock to certain members of EHHI management at closing. In January 2020, members of the management team exercised the remaining SARs, and in February 2020, we settled those awards upon payment of approximately $101 million in cash. For additional information, see Note 14, Share-Based Payments

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our Provision for income tax expense of $34.5 million and $27.1 million for the three months ended March 31, 2021 and 2020, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by tax benefits resulting from share-based compensation windfalls.

Earnings per Common Share

Earnings per Common Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Earnings per Common Share	Earnings per Common Share The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): Three Months Ended March 31, 2021 2020 Basic: Numerator: Income from continuing operations $ 132.8 $ 108.8 Less: Net income attributable to noncontrolling interests included in continuing operations (25.5) (21.7) Less: Income allocated to participating securities (0.5) (0.3) Income from continuing operations attributable to Encompass Health common shareholders 106.8 86.8 Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders — (0.1) Net income attributable to Encompass Health common shareholders $ 106.8 $ 86.7 Denominator: Basic weighted average common shares outstanding 99.0 98.2 Basic earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.08 $ 0.88 Discontinued operations — — Net income $ 1.08 $ 0.88 Diluted: Numerator: Income from continuing operations $ 132.8 $ 108.8 Less: Net income attributable to noncontrolling interests included in continuing operations (25.5) (21.7) Income from continuing operations attributable to Encompass Health common shareholders 107.3 87.1 Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders — (0.1) Net income attributable to Encompass Health common shareholders $ 107.3 $ 87.0 Denominator: Diluted weighted average common shares outstanding 100.2 99.6 Diluted earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.07 $ 0.87 Discontinued operations — — Net income $ 1.07 $ 0.87 The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): Three Months Ended March 31, 2021 2020 Basic weighted average common shares outstanding 99.0 98.2 Restricted stock awards, dilutive stock options, and restricted stock units 1.2 1.4 Diluted weighted average common shares outstanding 100.2 99.6 See Note 17, Earnings per Common Share

Contingencies and Other Commitm

Contingencies and Other Commitments	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Commitments	Contingencies and Other Commitments We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. Nichols Litigation— We were named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned Nichols v. HealthSouth Corp . In July 2019, we entered into settlement agreements with all but one plaintiff and paid those settling plaintiffs an aggregate amount of cash less than $0.1 million. The remaining plaintiff alleges that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiff is seeking compensatory and punitive damages. This case was stayed in the circuit court on August 8, 2005. However, the complaint has been amended from time to time, including to request certification as a class action. Additionally, one of the former officers named as a defendant has repeatedly attempted to remove the case to federal district court. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On December 10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lacked standing because their claims were derivative in nature, and the claims were time-barred by the statute of limitations. On May 26, 2016, the trial court granted our motion to dismiss. On appeal, the Supreme Court of Alabama reversed the trial court’s dismissal on March 23, 2018. On April 6, 2018, we filed an application for rehearing with the Alabama Supreme Court. On March 22, 2019, the Alabama Supreme Court denied our application for rehearing and remanded the case to the trial court for further proceedings. The court has not yet set a date for the trial to begin. On March 2, 2020, we filed a motion for summary judgment, which the trial court denied on June 17, 2020. On March 12, 2021 the Alabama Supreme Court directed the trial court to vacate its order that served as the basis for the denial of our motion for summary judgement. On April 7, 2021, we filed a renewed motion for summary judgment, the hearing for which has been scheduled on May 13, 2021. We intend to vigorously defend ourselves in this case against the sole remaining plaintiff. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate an amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. Other Matters— The False Claims Act allows private citizens, called “relators,” to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as “whistleblower” or “ qui tam ” actions, can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. Qui tam cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a qui tam action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that qui tam lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed qui tam cases brought pursuant to the False Claims Act. It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and the Centers for Medicare & Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments: • Inpatient Rehabilitation - Our national network of inpatient rehabilitation hospitals stretches across 35 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of March 31, 2021, we operate 138 inpatient rehabilitation hospitals. We are the sole owner of 86 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 52 jointly owned hospitals. In addition, we manage four inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. • Home Health and Hospice - As of March 31, 2021, we provide home health services in 241 locations and hospice services in 82 locations across 31 states with concentrations in the southern half of the United States. In addition, one of these home health agencies operates as a joint venture which we account for using the equity method of accounting. We are the sole owner of 317 of these locations. We retain 50.0% to 81.0% ownership in the remaining six jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Our hospice services include in-home services to terminally ill patients and their families to address patients’ physical needs, including pain control and symptom management, and to provide emotional and spiritual support. The accounting policies of our reportable segments are the same as those described in Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2020 Form 10‑K. All revenues for our services are generated through external customers. See Note 1, Basis of Presentation , “Net Operating Revenues,” for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (“Segment Adjusted EBITDA”). Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Three Months Ended March 31, Three Months Ended March 31, 2021 2020 2021 2020 Net operating revenues $ 959.9 $ 909.2 $ 270.5 $ 272.8 Operating expenses: Inpatient rehabilitation: Salaries and benefits 501.9 482.3 — — Other operating expenses 140.0 134.7 — — Supplies 45.2 39.6 — — Occupancy costs 15.1 15.3 — — Home health and hospice: Cost of service (excluding depreciation and amortization) — — 118.1 130.9 Support and overhead costs — — 101.4 100.2 702.2 671.9 219.5 231.1 Other (income) expense (1.5) 1.6 — — Equity in net income of nonconsolidated affiliates (0.8) (0.6) (0.2) (0.2) Noncontrolling interests 25.1 20.8 0.4 0.9 Segment Adjusted EBITDA $ 234.9 $ 215.5 $ 50.8 $ 41.0 Capital expenditures $ 99.8 $ 83.3 $ 0.9 $ 1.5 Segment reconciliations (in millions): Three Months Ended March 31, 2021 2020 Total Segment Adjusted EBITDA $ 285.7 $ 256.5 General and administrative expenses (38.6) (35.6) Depreciation and amortization (62.5) (58.8) Gain (loss) on disposal or impairment of assets 0.1 (0.1) Government, class action, and related settlements — (2.8) Interest expense and amortization of debt discounts and fees (42.8) (43.2) Net income attributable to noncontrolling interests 25.5 21.7 Change in fair market value of equity securities (0.1) (2.5) Gain on consolidation of joint venture formerly accounted for under the equity method of accounting — 2.2 Payroll taxes on SARs exercise — (1.5) Income from continuing operations before income tax expense $ 167.3 $ 135.9 Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended March 31, 2021 2020 Inpatient rehabilitation: Inpatient $ 942.3 $ 890.0 Outpatient and other 17.6 19.2 Total inpatient rehabilitation 959.9 909.2 Home health and hospice: Home health 219.9 224.8 Hospice 50.6 48.0 Total home health and hospice 270.5 272.8 Total net operating revenues $ 1,230.4 $ 1,182.0

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements — In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. Either prospective or retrospective transition of this standard is dependent upon the specific amendments. The new guidance was effective for us beginning January 1, 2021. The adoption of this guidance did not have a material impact to our condensed consolidated financial statements. We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Concentration of Net Operating Revenues by Payor	Our Net operating revenues disaggregated by payor source and segment are as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Consolidated Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, 2021 2020 2021 2020 2021 2020 Medicare $ 614.5 $ 641.9 $ 223.9 $ 226.2 $ 838.4 $ 868.1 Medicare Advantage 158.4 111.5 28.0 29.4 186.4 140.9 Managed care 112.2 90.2 14.3 12.1 126.5 102.3 Medicaid 39.0 30.7 3.8 4.2 42.8 34.9 Other third-party payors 12.1 11.0 — — 12.1 11.0 Workers’ compensation 5.7 6.9 0.1 0.3 5.8 7.2 Patients 4.9 5.5 0.2 0.4 5.1 5.9 Other income 13.1 11.5 0.2 0.2 13.3 11.7 Total $ 959.9 $ 909.2 $ 270.5 $ 272.8 $ 1,230.4 $ 1,182.0

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities	The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our condensed consolidated balance sheet, are as follows (in millions): March 31, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 0.5 $ 0.1 Accounts receivable 33.7 33.1 Other current assets 8.5 8.6 Total current assets 42.7 41.8 Property and equipment, net 118.7 121.1 Operating lease right-of-use assets 4.4 4.7 Goodwill 19.2 19.2 Intangible assets, net 3.1 3.3 Other long-term assets 31.1 31.1 Total assets $ 219.2 $ 221.2 Liabilities Current liabilities: Current portion of long-term debt $ 0.9 $ 0.9 Current operating lease liabilities 1.5 1.5 Accounts payable 5.9 6.1 Accrued expenses and other current liabilities 21.7 23.0 Total current liabilities 30.0 31.5 Long-term debt, net of current portion 9.4 9.6 Long-term operating lease liabilities 2.9 3.3 Other long-term liabilities 2.3 2.4 Total liabilities $ 44.6 $ 46.8

Long-term Debt (Tables)

Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of Outstanding Long-term Debt	Our long-term debt outstanding consists of the following (in millions): March 31, 2021 December 31, 2020 Credit Agreement— Term loan facilities $ 248.3 $ 251.6 Bonds payable— 5.125% Senior Notes due 2023 298.3 298.1 5.75% Senior Notes due 2025 346.5 346.3 4.50% Senior Notes due 2028 785.5 785.0 4.75% Senior Notes due 2030 783.5 783.2 4.625% Senior Notes due 2031 393.3 393.2 Other notes payable 39.7 39.8 Finance lease obligations 402.1 391.7 3,297.2 3,288.9 Less: Current portion (137.2) (38.3) Long-term debt, net of current portion $ 3,160.0 $ 3,250.6

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interests (Tables)	3 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interests Activity	The following is a summary of the activity related to our Redeemable noncontrolling interests (in millions): Three Months Ended March 31, 2021 2020 Balance at beginning of period $ 31.6 $ 239.6 Net income attributable to noncontrolling interests 2.4 2.0 Distributions declared (2.3) (2.1) Contribution to joint venture — 3.1 Purchase of redeemable noncontrolling interests — (162.3) Exchange transaction — (46.3) Balance at end of period $ 31.7 $ 34.0
Reconciliation of Noncontrolling Interests	The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net and comprehensive income attributable to noncontrolling interests presented in the condensed consolidated statements of comprehensive income (in millions): Three Months Ended March 31, 2021 2020 Net income attributable to nonredeemable noncontrolling interests $ 23.1 $ 19.7 Net income attributable to redeemable noncontrolling interests 2.4 2.0 Net income attributable to noncontrolling interests $ 25.5 $ 21.7

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis	Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of March 31, 2021 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Valuation Technique (1) Other long-term assets: Equity securities $ 73.1 $ — $ 73.1 $ — M Redeemable noncontrolling interests 31.7 — — 31.7 I As of December 31, 2020 Other long-term assets: Equity securities $ 72.6 $ — $ 72.6 $ — M Redeemable noncontrolling interests 31.6 — — 31.6 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I).
Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments	The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions): As of March 31, 2021 As of December 31, 2020 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Term loan facilities $ 248.3 $ 249.8 $ 251.6 $ 253.1 5.125% Senior Notes due 2023 298.3 300.8 298.1 302.6 5.75% Senior Notes due 2025 346.5 361.6 346.3 361.4 4.50% Senior Notes due 2028 785.5 820.2 785.0 840.0 4.75% Senior Notes due 2030 783.5 824.0 783.2 856.0 4.625% Senior Notes due 2031 393.3 415.0 393.2 424.9 Other notes payable 39.7 39.7 39.8 39.8 Financial commitments: Letters of credit — 37.7 — 36.7

Earnings per Common Share (Tabl

Earnings per Common Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Common Share	The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): Three Months Ended March 31, 2021 2020 Basic: Numerator: Income from continuing operations $ 132.8 $ 108.8 Less: Net income attributable to noncontrolling interests included in continuing operations (25.5) (21.7) Less: Income allocated to participating securities (0.5) (0.3) Income from continuing operations attributable to Encompass Health common shareholders 106.8 86.8 Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders — (0.1) Net income attributable to Encompass Health common shareholders $ 106.8 $ 86.7 Denominator: Basic weighted average common shares outstanding 99.0 98.2 Basic earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.08 $ 0.88 Discontinued operations — — Net income $ 1.08 $ 0.88 Diluted: Numerator: Income from continuing operations $ 132.8 $ 108.8 Less: Net income attributable to noncontrolling interests included in continuing operations (25.5) (21.7) Income from continuing operations attributable to Encompass Health common shareholders 107.3 87.1 Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders — (0.1) Net income attributable to Encompass Health common shareholders $ 107.3 $ 87.0 Denominator: Diluted weighted average common shares outstanding 100.2 99.6 Diluted earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.07 $ 0.87 Discontinued operations — — Net income $ 1.07 $ 0.87
Reconciliation of Weighted Average Number of Shares Outstanding	The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): Three Months Ended March 31, 2021 2020 Basic weighted average common shares outstanding 99.0 98.2 Restricted stock awards, dilutive stock options, and restricted stock units 1.2 1.4 Diluted weighted average common shares outstanding 100.2 99.6

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Three Months Ended March 31, Three Months Ended March 31, 2021 2020 2021 2020 Net operating revenues $ 959.9 $ 909.2 $ 270.5 $ 272.8 Operating expenses: Inpatient rehabilitation: Salaries and benefits 501.9 482.3 — — Other operating expenses 140.0 134.7 — — Supplies 45.2 39.6 — — Occupancy costs 15.1 15.3 — — Home health and hospice: Cost of service (excluding depreciation and amortization) — — 118.1 130.9 Support and overhead costs — — 101.4 100.2 702.2 671.9 219.5 231.1 Other (income) expense (1.5) 1.6 — — Equity in net income of nonconsolidated affiliates (0.8) (0.6) (0.2) (0.2) Noncontrolling interests 25.1 20.8 0.4 0.9 Segment Adjusted EBITDA $ 234.9 $ 215.5 $ 50.8 $ 41.0 Capital expenditures $ 99.8 $ 83.3 $ 0.9 $ 1.5
Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense	Segment reconciliations (in millions): Three Months Ended March 31, 2021 2020 Total Segment Adjusted EBITDA $ 285.7 $ 256.5 General and administrative expenses (38.6) (35.6) Depreciation and amortization (62.5) (58.8) Gain (loss) on disposal or impairment of assets 0.1 (0.1) Government, class action, and related settlements — (2.8) Interest expense and amortization of debt discounts and fees (42.8) (43.2) Net income attributable to noncontrolling interests 25.5 21.7 Change in fair market value of equity securities (0.1) (2.5) Gain on consolidation of joint venture formerly accounted for under the equity method of accounting — 2.2 Payroll taxes on SARs exercise — (1.5) Income from continuing operations before income tax expense $ 167.3 $ 135.9
Reconciliation of Revenue from Segments to Consolidated	Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended March 31, 2021 2020 Inpatient rehabilitation: Inpatient $ 942.3 $ 890.0 Outpatient and other 17.6 19.2 Total inpatient rehabilitation 959.9 909.2 Home health and hospice: Home health 219.9 224.8 Hospice 50.6 48.0 Total home health and hospice 270.5 272.8 Total net operating revenues $ 1,230.4 $ 1,182.0

Basis of Presentation - Textual

Basis of Presentation - Textual (Details)	3 Months Ended
	Mar. 31, 2021statesegment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of states in which entity operates | state	39
Number of operating segments | segment	2

Basis of Presentation - Net Ope

Basis of Presentation - Net Operating Revenues (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Net operating revenues	$ 1,230.4	$ 1,182
Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	959.9	909.2
Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	270.5	272.8
Medicare
Disaggregation of Revenue [Line Items]
Net operating revenues	838.4	868.1
Medicare | Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	614.5	641.9
Medicare | Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	223.9	226.2
Medicare Advantage
Disaggregation of Revenue [Line Items]
Net operating revenues	186.4	140.9
Medicare Advantage | Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	158.4	111.5
Medicare Advantage | Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	28	29.4
Managed care
Disaggregation of Revenue [Line Items]
Net operating revenues	126.5	102.3
Managed care | Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	112.2	90.2
Managed care | Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	14.3	12.1
Medicaid
Disaggregation of Revenue [Line Items]
Net operating revenues	42.8	34.9
Medicaid | Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	39	30.7
Medicaid | Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	3.8	4.2
Other third-party payors
Disaggregation of Revenue [Line Items]
Net operating revenues	12.1	11
Other third-party payors | Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	12.1	11
Other third-party payors | Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	0	0
Workers’ compensation
Disaggregation of Revenue [Line Items]
Net operating revenues	5.8	7.2
Workers’ compensation | Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	5.7	6.9
Workers’ compensation | Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	0.1	0.3
Patients
Disaggregation of Revenue [Line Items]
Net operating revenues	5.1	5.9
Patients | Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	4.9	5.5
Patients | Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	0.2	0.4
Other income
Disaggregation of Revenue [Line Items]
Net operating revenues	13.3	11.7
Other income | Inpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Net operating revenues	13.1	11.5
Other income | Home Health and Hospice
Disaggregation of Revenue [Line Items]
Net operating revenues	$ 0.2	$ 0.2

Business Combinations - Textual

Business Combinations - Textual (Details) - Home Health and Hospice - Subsequent Event $ in Millions	1 Months Ended
	Apr. 30, 2021USD ($)location
Business Acquisition [Line Items]
Payments to acquire businesses, gross | $	$ 95
Home health
Business Acquisition [Line Items]
Number of locations	9
Hospice
Business Acquisition [Line Items]
Number of locations	11

Variable Interest Entities - Te

Variable Interest Entities - Textual (Details) - VIE - entity	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Number of consolidated limited partnership-like entities	9	9
Minimum
Variable Interest Entity [Line Items]
Ownership interest in consolidated entities (percent)	50.00%
Maximum
Variable Interest Entity [Line Items]
Ownership interest in consolidated entities (percent)	75.00%

Variable Interest Entities - Sc

Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details) - USD ($) $ in Millions		Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents		$ 223.9	$ 224	$ 104.9	$ 94.8
Accounts receivable		633.6	572.8
Other current assets		81.4	86.4
Total current assets		1,001.1	948.6
Property and equipment, net		2,280.5	2,206.6
Operating lease right-of-use assets		248.3	245.7
Goodwill		2,318.7	2,318.7
Intangible assets, net		419.2	431.3
Other long-term assets		274.4	295
Total assets	[1]	6,542.2	6,445.9
Current liabilities:
Current portion of long-term debt		137.2	38.3
Current operating lease liabilities		44.2	44.8
Accounts payable		122.8	115
Accrued expenses and other current liabilities		508	519.2
Total current liabilities		812.2	717.3
Long-term debt, net of current portion		3,160	3,250.6
Long-term operating lease liabilities		214.2	209.6
Other long-term liabilities		220.5	215
Total liabilities		4,467.5	4,444.3
VIE
Current assets:
Cash and cash equivalents		0.5	0.1
Accounts receivable		33.7	33.1
Other current assets		8.5	8.6
Total current assets		42.7	41.8
Property and equipment, net		118.7	121.1
Operating lease right-of-use assets		4.4	4.7
Goodwill		19.2	19.2
Intangible assets, net		3.1	3.3
Other long-term assets		31.1	31.1
Total assets		219.2	221.2
Current liabilities:
Current portion of long-term debt		0.9	0.9
Current operating lease liabilities		1.5	1.5
Accounts payable		5.9	6.1
Accrued expenses and other current liabilities		21.7	23
Total current liabilities		30	31.5
Long-term debt, net of current portion		9.4	9.6
Long-term operating lease liabilities		2.9	3.3
Other long-term liabilities		2.3	2.4
Total liabilities		$ 44.6	$ 46.8
[1]	Our consolidated assets as of March 31, 2021 and December 31, 2020 include total assets of variable interest entities of $219.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2021 and December 31, 2020 include total liabilities of the variable interest entities of $44.6 million and $46.8 million, respectively. See Note 3, Variable Interest Entities.

Long-term Debt - Long-term Debt

Long-term Debt - Long-term Debt Outstanding (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Schedule of Outstanding Long-term Debt
Finance lease obligations	$ 402.1	$ 391.7
Total debt and finance lease obligations	3,297.2	3,288.9
Less: Current portion	(137.2)	(38.3)
Long-term debt, net of current portion	3,160	3,250.6
Term loan facilities | Term loan facilities
Schedule of Outstanding Long-term Debt
Total debt	$ 248.3	$ 251.6
Senior Notes | 5.125% Senior Notes due 2023
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	5.125%	5.125%
Total debt	$ 298.3	$ 298.1
Senior Notes | 5.75% Senior Notes due 2025
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	5.75%	5.75%
Total debt	$ 346.5	$ 346.3
Senior Notes | 4.50% Senior Notes due 2028
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	4.50%	4.50%
Total debt	$ 785.5	$ 785
Senior Notes | 4.75% Senior Notes due 2030
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	4.75%	4.75%
Total debt	$ 783.5	$ 783.2
Senior Notes | 4.625% Senior Notes due 2031
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	4.625%	4.625%
Total debt	$ 393.3	$ 393.2
Other notes payable
Schedule of Outstanding Long-term Debt
Total debt	$ 39.7	$ 39.8

Long-term Debt - Textual (Detai

Long-term Debt - Textual (Details) - Senior Notes - 5.125% Senior Notes due 2023 - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Redemption amount		$ 100
Debt instrument interest rate (percent)		5.125%	5.125%
Long-term debt		$ 100
Forecast
Debt Instrument [Line Items]
Loss on early extinguishment of debt	$ 0.6

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]
Balance at beginning of period	$ 31.6
Net income attributable to noncontrolling interests	2.4	$ 2
Distributions declared	(22.4)	(15.5)
Balance at end of period	31.7
Redeemable Noncontrolling Interest
Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]
Balance at beginning of period	31.6	239.6
Net income attributable to noncontrolling interests	2.4	2
Distributions declared	(2.3)	(2.1)
Contribution to joint venture	0	3.1
Purchase of redeemable noncontrolling interests	0	(162.3)
Exchange transaction	0	(46.3)
Balance at end of period	$ 31.7	$ 34

Redeemable Noncontrolling Int_4

Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Noncontrolling Interest [Abstract]
Net income attributable to nonredeemable noncontrolling interests	$ 23.1	$ 19.7
Net income attributable to redeemable noncontrolling interests	2.4	2
Net income attributable to noncontrolling interests	$ 25.5	$ 21.7

Redeemable Noncontrolling Int_5

Redeemable Noncontrolling Interests - Textual (Details) - USD ($) $ in Millions	Feb. 18, 2020	Jan. 31, 2020	Mar. 31, 2021	Dec. 31, 2020	Mar. 06, 2020	Feb. 20, 2020	Dec. 31, 2014
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interests			$ 31.7	$ 31.6
Percentage of shares exercised by investor		4.30%
Purchase of redeemable noncontrolling interests	$ 162
Temporary equity, shares issued (shares)						560,957
Temporary equity, shares to management investors exchange agreements percentages					0.60%
Holdings And EHHI
Noncontrolling Interest [Line Items]
Ownership percentage			100.00%
EHHI
Noncontrolling Interest [Line Items]
Outstanding common stock of Holdings, fair value	$ 46
EHHI | Home Health and Hospice
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interest, equity, acquired percent							83.30%
Redeemable noncontrolling interests							$ 64
Subsidiary's common stock held by subsidiary 's management, percent							16.70%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Equity securities	$ 73.1	$ 72.6
Redeemable noncontrolling interests	31.7	31.6
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Equity securities	0	0
Redeemable noncontrolling interests	0	0
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Equity securities	73.1	72.6
Redeemable noncontrolling interests	0	0
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Equity securities	0	0
Redeemable noncontrolling interests	$ 31.7	$ 31.6

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Term loan facilities | Term loan facilities | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 248.3	$ 251.6
Term loan facilities | Term loan facilities | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 249.8	$ 253.1
Senior Notes | 5.125% Senior Notes due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	5.125%	5.125%
Senior Notes | 5.125% Senior Notes due 2023 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 298.3	$ 298.1
Senior Notes | 5.125% Senior Notes due 2023 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 300.8	$ 302.6
Senior Notes | 5.75% Senior Notes due 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	5.75%	5.75%
Senior Notes | 5.75% Senior Notes due 2025 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 346.5	$ 346.3
Senior Notes | 5.75% Senior Notes due 2025 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 361.6	$ 361.4
Senior Notes | 4.50% Senior Notes due 2028
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	4.50%	4.50%
Senior Notes | 4.50% Senior Notes due 2028 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 785.5	$ 785
Senior Notes | 4.50% Senior Notes due 2028 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 820.2	$ 840
Senior Notes | 4.75% Senior Notes due 2030
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	4.75%	4.75%
Senior Notes | 4.75% Senior Notes due 2030 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 783.5	$ 783.2
Senior Notes | 4.75% Senior Notes due 2030 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 824	$ 856
Senior Notes | 4.625% Senior Notes due 2031
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	4.625%	4.625%
Senior Notes | 4.625% Senior Notes due 2031 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 393.3	$ 393.2
Senior Notes | 4.625% Senior Notes due 2031 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	415	424.9
Other notes payable | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	39.7	39.8
Other notes payable | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	39.7	39.8
Letters of credit | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	0	0
Letters of credit | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 37.7	$ 36.7

Share-Based Payments (Details)

Share-Based Payments (Details) - USD ($) shares in Millions, $ in Millions	1 Months Ended	3 Months Ended
	Feb. 29, 2020	Mar. 31, 2021
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards issued (shares)		0.5
Restricted Stock | Service Condition
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards issued (shares)		0.2
Restricted Stock | Service and Performance Condition
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance measurement period		2 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (shares)		0.1
SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash used to settle award	$ 101

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income tax expense	$ 34.5	$ 27.1

Earnings per Common Share - Com

Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Basic Numerator:
Income from continuing operations	$ 132.8	$ 108.8
Less: Net income attributable to noncontrolling interests included in continuing operations	(25.5)	(21.7)
Less: Income allocated to participating securities	(0.5)	(0.3)
Income from continuing operations attributable to Encompass Health common shareholders	106.8	86.8
Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders	0	(0.1)
Net income attributable to Encompass Health common shareholders	$ 106.8	$ 86.7
Basic Denominator:
Basic weighted average common shares outstanding (in shares)	99	98.2
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations (in dollars per share)	$ 1.08	$ 0.88
Discontinued operations (in dollars per share)	0	0
Net income (in dollars per share)	$ 1.08	$ 0.88
Diluted Numerator
Income from continuing operations	$ 132.8	$ 108.8
Less: Net income attributable to noncontrolling interests included in continuing operations	(25.5)	(21.7)
Income from continuing operations attributable to Encompass Health common shareholders	107.3	87.1
Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders	0	(0.1)
Net income attributable to Encompass Health common shareholders	$ 107.3	$ 87
Diluted Denominator
Diluted weighted average common shares outstanding (in shares)	100.2	99.6
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations (in dollars per share)	$ 1.07	$ 0.87
Discontinued operations (in dollars per share)	0	0
Net income (in dollars per share)	$ 1.07	$ 0.87

Earnings per Common Share - Rec

Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Basic weighted average common shares outstanding (in shares)	99	98.2
Restricted stock awards, dilutive stock options, and restricted stock units (shares)	1.2	1.4
Diluted weighted average common shares outstanding (in shares)	100.2	99.6

Contingencies and Other Commi_2

Contingencies and Other Commitments (Details) $ in Millions	1 Months Ended
	Jul. 31, 2019USD ($)
Maximum | Settled Litigation | Nichols Litigation
Loss Contingencies [Line Items]
Cash payment for litigation settlement	$ 0.1

Segment Reporting - Textual (De

Segment Reporting - Textual (Details)	3 Months Ended
	Mar. 31, 2021statehospitallocationsegment
Segment Reporting Information [Line Items]
Number of operating segments | segment	2
Number of states in which entity operates | state	39
Inpatient Rehabilitation
Segment Reporting Information [Line Items]
Number of states in which entity operates | state	35
Number of inpatient rehabilitation hospitals operated	138
Number of solely owned inpatient rehabilitation hospitals	86
Number of jointly owned inpatient rehabilitation hospitals	52
Number of inpatient rehabilitation units under management contracts	4
Inpatient Rehabilitation | Minimum
Segment Reporting Information [Line Items]
Joint venture ownership percentage	50.00%
Inpatient Rehabilitation | Maximum
Segment Reporting Information [Line Items]
Joint venture ownership percentage	97.50%
Home Health and Hospice
Segment Reporting Information [Line Items]
Number of states in which entity operates | state	31
Number of home health locations | location	241
Number of hospice locations | location	82
Number of hospitals or agencies operated as a joint venture	1
Number of solely owned hospital based home health and hospice locations | location	317
Number of jointly owned hospital based home health and hospice locations | location	6
Home Health and Hospice | Minimum
Segment Reporting Information [Line Items]
Joint venture ownership percentage	50.00%
Home Health and Hospice | Maximum
Segment Reporting Information [Line Items]
Joint venture ownership percentage	81.00%

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Net operating revenues	$ 1,230.4	$ 1,182
Operating expenses:
Salaries and benefits	687.2	679.1
Other operating expenses	162.3	159.6
Supplies	51.9	45.7
Occupancy costs	20.2	20.2
Total operating expenses	1,022.7	1,001.8
Other (income) expense	(1.4)	1.9
Equity in net income of nonconsolidated affiliates	(1)	(0.8)
Noncontrolling interests	25.5	21.7
Inpatient Rehabilitation
Segment Reporting Information [Line Items]
Net operating revenues	959.9	909.2
Operating expenses:
Salaries and benefits	501.9	482.3
Other operating expenses	140	134.7
Supplies	45.2	39.6
Occupancy costs	15.1	15.3
Cost of service (excluding depreciation and amortization)	0	0
Support and overhead costs	0	0
Total operating expenses	702.2	671.9
Other (income) expense	(1.5)	1.6
Equity in net income of nonconsolidated affiliates	(0.8)	(0.6)
Noncontrolling interests	25.1	20.8
Segment Adjusted EBITDA	234.9	215.5
Capital expenditures	99.8	83.3
Home Health and Hospice
Segment Reporting Information [Line Items]
Net operating revenues	270.5	272.8
Operating expenses:
Salaries and benefits	0	0
Other operating expenses	0	0
Supplies	0	0
Occupancy costs	0	0
Cost of service (excluding depreciation and amortization)	118.1	130.9
Support and overhead costs	101.4	100.2
Total operating expenses	219.5	231.1
Other (income) expense	0	0
Equity in net income of nonconsolidated affiliates	(0.2)	(0.2)
Noncontrolling interests	0.4	0.9
Segment Adjusted EBITDA	50.8	41
Capital expenditures	$ 0.9	$ 1.5

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
General and administrative expenses	$ (38.6)	$ (35.6)
Depreciation and amortization	(62.5)	(58.8)
Government, class action, and related settlements	0	(2.8)
Net income attributable to noncontrolling interests	25.5	21.7
Income from continuing operations before income tax expense	167.3	135.9
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total Segment Adjusted EBITDA	285.7	256.5
Segment Reconciling Items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
General and administrative expenses	(38.6)	(35.6)
Depreciation and amortization	(62.5)	(58.8)
Gain (loss) on disposal or impairment of assets	0.1	(0.1)
Government, class action, and related settlements	0	(2.8)
Interest expense and amortization of debt discounts and fees	(42.8)	(43.2)
Net income attributable to noncontrolling interests	25.5	21.7
Change in fair market value of equity securities	(0.1)	(2.5)
Gain on consolidation of joint venture formerly accounted for under the equity method of accounting	0	2.2
Payroll taxes on SARs exercise	$ 0	$ (1.5)

Segment Reporting - Reconcili_2

Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 1,230.4	$ 1,182
Inpatient Rehabilitation
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	959.9	909.2
Inpatient Rehabilitation | Inpatient
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	942.3	890
Inpatient Rehabilitation | Outpatient and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	17.6	19.2
Home Health and Hospice
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	270.5	272.8
Home Health and Hospice | Home health
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	219.9	224.8
Home Health and Hospice | Hospice
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 50.6	$ 48